XOMA Corporation
NASDAQ:XOMAP · NASDAQ Global Market
+$0.02 today
Vol 0.00M · Avg 0.00M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
30.5%
avg 105.7%
ROIC
4.5%
avg -47.2%
ROA
11.6%
avg -19.0%
Analysis
ROE is currently the strongest return metric at 30.5% versus its period average of 105.7%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Owen Hughes Jr. | Chief Executive Officer & Director | $1.14M | — | 51 | $275,000.00 | 2.28% |
Brad Sitko | Chief Investment Officer | $853,495.00 | — | 45 | $5,600.00 | 0.05% |
Juliane Snowden | Head of Investor Relations | — | — | — | — | — |
Jeffrey Trigilio | Chief Financial Officer | — | — | 42 | — | — |
Maricel Perea Montano | Chief Legal Officer & Corporate Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +18.0% | +2.4% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +18.0% over three years. Forward estimates point to Revenue at +2.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Tectonic Therapeutic, Inc.
NASDAQ:TECX
$562.30M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$350.28M
Amarin Corporation plc
NASDAQ:AMRN
$330.93M
Silence Therapeutics plc
NASDAQ:SLN
$327.57M
Cellectis S.A.
NASDAQ:CLLS
$307.28M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$305.94M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$294.56M
AC Immune S.A.
NASDAQ:ACIU
$241.71M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$117.32M
Genelux Corporation
NASDAQ:GNLX
$110.03M
Who manages XOMAP?
XOMA Corporation (XOMAP) lists 5 active executives. The top listed executive is Juliane Snowden, Head of Investor Relations.
Are XOMAP insiders buying or selling?
Recent insider activity shows net buying of $28.61M.
Explore More
Continue the stock analysis
Jump to another research area for this company.